Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director · President & CEO | October 12, 2026 | October 13, 2026 |
| Gamida Cell Ltd.GMDA · Entity 94655 | Director | February 08, 2023 | February 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,544 |
Ending reported balance
After 2026-10-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-12 · Exercise / conversion · Acquired 7,500 · Balance 286,044 Row 2 · 2026-10-12 · Sale · Disposed 7,500 · Balance 278,544 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2027-02-28 | Direct | 141,745 |
Reported balance
After 2026-10-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-12 · Exercise / conversion · Disposed 7,500 · Balance 141,745 |
| Common StockSEC Table I · non-derivative | Indirectby Trust 1. Beneficial Ownership disclaimed. | 2,083 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,083 F1: Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares. |
| Common StockSEC Table I · non-derivative | Indirectby Trust 2. Beneficial Ownership Disclaimed. | 2,083 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,083 F2: Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
F2: Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
Gamida Cell Ltd.
Report date February 08, 2023 · Filed February 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 96,500 |
Ending reported balance
After 2023-02-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-08 · Grant · Acquired 28,300 · Balance 82,300 F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. Row 2 · 2023-02-08 · Grant · Acquired 14,200 · Balance 96,500 F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2033-02-07 | Direct | 56,600 |
Reported balance
After 2023-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-08 · Grant · Acquired 56,600 · Balance 56,600 F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2033-02-07 | Direct | 28,300 |
Reported balance
After 2023-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-02-08 · Grant · Acquired 28,300 · Balance 28,300 F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date.
F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2024 Filed Jul 31, 2024 20:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-021230 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,227 Underlying: Common Stock · 11,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,500 | $59.49 | $684,135.00 |
DisclosureSEC source: 0001127602-24-021230 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,412 Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,500 | $6.67 | $76,705.00 |
DisclosureSEC source: 0001127602-24-021230 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2024 Filed Jul 10, 2024 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,767 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-020275 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,727 Underlying: Common Stock · 5,767 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2024 Filed Jul 10, 2024 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,500 | $54.29 | $624,335.00 |
DisclosureSEC source: 0001127602-24-020275 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,412 Read SEC document |
| July 10, 2024 Filed Jul 10, 2024 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,767 | $6.67 | $38,465.89 |
DisclosureSEC source: 0001127602-24-020275 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,500 | $54.05 | $621,575.00 |
DisclosureSEC source: 0001127602-24-019613 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,145 Read SEC document |
| June 17, 2024 Filed Jun 17, 2024 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,949 | $52.59 | $575,807.91 |
DisclosureSEC source: 0001127602-24-018855 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,645 Read SEC document |
| June 17, 2024 Filed Jun 17, 2024 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,551 | $52.60 | $607,582.60 |
DisclosureSEC source: 0001127602-24-018855 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,594 Read SEC document |
| June 04, 2024 Filed Jun 7, 2024 20:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 22,500 | $48.85 | $1,099,125.00 |
DisclosureSEC source: 0001127602-24-018143 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,145 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 5, 2024. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 69,464 | $0.00 Strike: $63.75 | $0.00 |
DisclosureSEC source: 0001127602-24-010515 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,464 Underlying: Common Stock · 69,464 shares Expires 2034-03-14 F4 · kind: Award comprised of Non Statutory Stock Options that will vest and become exercisable over 4 years in monthly installments starting April 15, 2024, with the final monthly installment vesting on March 14, 2028. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 1,568 | $0.00 Strike: $63.75 | $0.00 |
DisclosureSEC source: 0001127602-24-010515 · form4.xml · derivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,568 Underlying: Common Stock · 1,568 shares Expires 2034-03-14 F4 · kind: Award comprised of Non Statutory Stock Options that will vest and become exercisable over 4 years in monthly installments starting April 15, 2024, with the final monthly installment vesting on March 14, 2028. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 61,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-010515 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,221 F1 · kind: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an addiitional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 16,725 | $66.88 | $1,118,568.00 |
DisclosureSEC source: 0001127602-24-009013 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,731 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 25,341 | $67.68 | $1,715,078.88 |
DisclosureSEC source: 0001127602-24-009013 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,456 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-004668 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,494 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $76.85 | $960,625.00 |
DisclosureSEC source: 0001127602-24-004668 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,797 F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-24-004668 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-003154 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,994 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $79.57 | $994,625.00 |
DisclosureSEC source: 0001127602-24-003154 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,797 F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-24-003154 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 19, 2024 Filed Jan 22, 2024 22:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-001841 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,494 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 19, 2024 Filed Jan 22, 2024 22:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $81.42 | $1,017,750.00 |
DisclosureSEC source: 0001127602-24-001841 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,797 F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 19, 2024 Filed Jan 22, 2024 22:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-24-001841 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-000165 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,994 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $85.08 | $1,063,500.00 |
DisclosureSEC source: 0001127602-24-000165 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,797 F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-24-000165 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-030013 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,494 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $36.95 | $461,875.00 |
DisclosureSEC source: 0001127602-23-030013 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,797 F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-23-030013 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 27, 2022. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-028595 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,994 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $32.99 | $412,375.00 |
DisclosureSEC source: 0001127602-23-028595 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,417 Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-23-028595 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2023 Filed Nov 15, 2023 22:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-027443 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,494 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2023 Filed Nov 15, 2023 22:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $34.57 | $432,125.00 |
DisclosureSEC source: 0001127602-23-027443 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,417 Read SEC document |
| November 15, 2023 Filed Nov 15, 2023 22:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-23-027443 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2023 Filed Oct 30, 2023 20:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-026356 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,994 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2023 Filed Oct 30, 2023 20:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $32.17 | $402,125.00 |
DisclosureSEC source: 0001127602-23-026356 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,417 Read SEC document |
| October 30, 2023 Filed Oct 30, 2023 20:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-23-026356 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-025923 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,494 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $33.70 | $421,250.00 |
DisclosureSEC source: 0001127602-23-025923 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,417 Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-23-025923 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 20:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-025680 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,994 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 20:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $30.00 | $375,000.00 |
DisclosureSEC source: 0001127602-23-025680 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,417 Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 20:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-23-025680 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-024067 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,494 Underlying: Common Stock · 12,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 12,500 | $34.90 | $436,206.25 |
DisclosureSEC source: 0001127602-23-024067 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,417 Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 12,500 | $6.67 | $83,375.00 |
DisclosureSEC source: 0001127602-23-024067 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 22:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-23-023304 · form4.xml · derivative · entry 7 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 22:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-23-023304 · form4.xml · derivative · entry 6 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,994 Underlying: Common Stock · 2,500 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.